Clinical Research Directory
Browse clinical research sites, groups, and studies.
Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events
Sponsor: Sanofi
Summary
To estimate ischemic event rates in individuals with established atherosclerotic cardiovascular disease (ASCVD) and no prior acute ischemic events, comparing alirocumab with no Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitor therapy, using a target trial emulation of routine clinical practice data.
Official title: Alirocumab and Cardiovascular Outcomes in Patients Without a Previous Myocardial Infarction or Stroke
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
4006
Start Date
2025-07-15
Completion Date
2026-08-15
Last Updated
2026-09-11
Healthy Volunteers
No
Interventions
Alirocumab
The study will not administer any treatment, only observe the treatment as prescribed in routine clinical practice.
Comparator: No PCSK9i Therapy (monoclonal antibodies or small interfering RNA agents)
The study will not administer any treatment, only observe the treatment as prescribed in routine clinical practice.
Locations (1)
Sanofi
Amsterdam, Netherlands